期刊
ANNUAL REVIEW OF MEDICINE, VOL 70
卷 70, 期 -, 页码 307-321出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-041217-010829
关键词
antisense oligonucleotides; eteplirsen; inotersen; nusinersen; patisiran; RNA interference; RNA splicing; siRNA
The first published description of therapeutic applications of antisense oligonucleotide (ASO) technology occurred in the late 1970s and was followed by the founding of commercial companies focused on developing antisense therapeutics in the late 1980s. Since the late 1980s, there has been steady progress in improving the technology platform, taking advantage of advances in oligonucleotide chemistry and formulations as well as increased understanding of the distribution and safety of ASOs. There are several approved ASO drugs and a broad pipeline in development. In addition, advances in understanding human disease, including the genetic basis for most monogenic diseases and the availability of the full human genome sequence, have created numerous therapeutic applications for the technology. I summarize the state of the technology and highlight how advances in the technology position ASOs to be an important contributor to future medicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据